We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554), today announced its commitment to CBT Pharmaceuticals as a leader in the discovery and development of cancer combination therapies.